Market cap, ratios, CAGR and revenue: company table snapshot as of 6 Nov 2026 (the same figures on every page). Price: snapshot as of 6 Nov 2026. Not investment advice.
Where it fits
Collects samples through patient service centres, home collection and hospital tie-ups, and runs them through regional reference labs: routine blood work, wellness packages and specialised tests (genomics, oncology markers). Organised chains compete with standalone labs and with hospitals' in-house labs.
Why it matters
Diagnostics is asset-light with high returns, and it is where most clinical decisions start. Organised players hold a minority of a fragmented market, so share gains from small labs drive growth - but low entry barriers bring repeated price wars.
Where the value pool sits
Leaders earn 25-30% EBITDA margins with low capex. Growth comes from volume (patients and tests per patient) and from specialised and wellness tests; routine-test prices have been flat to falling.
Key drivers
Preventive health and chronic-disease monitoring
Expansion into new cities through acquisitions (Metropolis, Dr Lal)
Specialised and genomic testing
Potential bottlenecks
Price competition from online aggregators and hospital chains
Logistics of sample collection in smaller towns
Little regulation of lab quality (NABL accreditation is voluntary)